ABUS
Arbutus Biopharma CorporationNASDAQHealthcare$4.48-0.88%ClosedMarket Cap: $875.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
11.16
P/S
61.91
EV/EBITDA
-23.22
DCF Value
$-2.61
FCF Yield
-4.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
36.2%
Operating Margin
-348.7%
Net Margin
-237.9%
ROE
-42.4%
ROA
-35.4%
ROIC
-55.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.1M | 99.0% | $-7.6M | $-3.8M | $-0.02 | — |
| FY 2025 | $14.1M | 97.4% | $-27.1M | $-33.5M | $-0.17 | — |
| Q3 2025 | $529.0K | 97.9% | $-8.3M | $-7.7M | $-0.04 | — |
| Q2 2025 | $10.7M | 100.0% | $1.5M | $2.5M | $0.01 | — |
| Q1 2025 | $1.8M | -407.9% | $-34.7M | $-24.5M | $-0.13 | — |
| Q4 2024 | $1.6M | -459.7% | $-13.9M | $-12.5M | $-0.07 | — |
| FY 2024 | $6.2M | 100.0% | $-76.3M | $-69.9M | $-0.38 | — |
| Q3 2024 | $1.3M | 100.0% | $-21.4M | $-19.7M | $-0.10 | — |
| Q2 2024 | $1.7M | 100.0% | $-21.6M | $-19.8M | $-0.11 | — |
| Q1 2024 | $1.5M | 100.0% | $-19.4M | $-17.9M | $-0.10 | — |
| Q4 2023 | $2.1M | -718.8% | $-20.7M | $-19.3M | $-0.11 | — |
| FY 2023 | $18.1M | 100.0% | $-78.1M | $-72.8M | $-0.44 | — |